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Background: Rhabdophis tigrinus (Yamakagashi snake) is a rear-fanged colubrid snake present throughout Russia
and Asia. Its venom induces life-threatening hemorrhagic symptoms and severe disseminated intravascular coagulation
with a fibrinolytic phenotype.
R. tigrinus antivenom manufactured by the immunization of horses to neutralize the venom has the risk of adverse
events such as anaphylaxis and serum sickness disease. It should be used when benefit is greater than the risk of
adverse effects; however, its efficacy has not been well evaluated.
Although our previous survey of nine cases demonstrated that seven of all cases treated with antivenom survived, the
clinical characteristics and prognosis without antivenom administration remained unclear. We assumed that R. tigrinus
antivenom administration overlaps self-recovery with supportive care. We aimed to determine the association between
antivenom administration and outcome with further analyzed cases.
Methods: We retrospectively reviewed the records of the Japan Snake Institute between January 1, 1973 and
December 31, 2013. Antivenom and without antivenom groups were compared with regard to baseline demographic
features, treatment-related factors, and outcomes.
Results: In total, 34 patients were analyzed (97% male, median age 37.5 years). Twenty-five patients were further
examined from our previous study. On admission, the median levels of fibrinogen and fibrinogen degradation
products were 35 mg/dL and 200 μg/mL, respectively, and platelet counts were 107,000/mm3. The median disseminated
intravascular coagulation score (defined by the Japanese Association of Acute Medicine) was 5. Antivenom was
administered to 19 patients, with a median interval of 32 h between bite and antivenom administration. The
in-hospital mortality rate was 12%. In univariate analysis, baseline characteristics and laboratory data were not
significantly different between the antivenom and without antivenom groups. Hospital mortality in the antivenom
group was significantly better than that in the without antivenom group (0% vs. 26.7%, P = 0.03). Moreover, the
number of patients developing renal failure requiring hemodialysis was significantly lower in the antivenom group
(5.3% vs. 40.0%, P = 0.03).
Conclusions: In our small retrospective study, antivenom administration was likely to be effective in the
management of R. tigrinus bites. Apparently, further research is required to confirm its efficacy.
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Rhabdophis tigrinus (Yamakagashi snake) is a rear-fanged
venomous snake present throughout Russia and Asia [1].
Its venom induces life-threatening hemorrhagic symptoms
and severe disseminated intravascular coagulation (DIC)
with a fibrinolytic phenotype [2].
R. tigrinus antivenom manufactured by the immunization
of horses to neutralize the venom has the risk of adverse
events such as anaphylaxis and serum sickness disease
[1,2]. It should be used when benefit is greater than the
risk of adverse effects; however, its efficacy has not been
well evaluated. Although our previous survey of nine cases
demonstrated that seven of all cases treated with anti-
venom survived, the clinical characteristics and prognosis
without antivenom administration remained unclear [3].
Further, theoretically, R. tigrinus antivenom only neutral-
izes the unbound venom and cannot restore organ func-
tion. Antivenom was administered after patients developed
severe DIC in the study (the median interval between bite
and antivenom administration was 35 h) [2]. We assume
that the R. tigrinus antivenom administration overlaps
self-recovery with supportive care.
The present study therefore aimed to determine the
association between antivenom administration and out-
come with further analyzed cases.Methods
The institutional review board of the Japan Snake Institute
approved the present study.Patients and setting
The Japan Snake Institute was established in 1968 to
research medical application of snakes.
In clinical practice, physicians managing patients with
snake bites usually ask for the assistance of the Japan
Snake Institute, where diagnosis is confirmed according
to laboratory data and clinical symptoms. Clinical data
was routinely collected, and all cases of R. tigrinus bites
were recorded in this institute. The records of the Japan
Snake Institute were retrospectively investigated between
January 1, 1973 and December 31, 2013.Diagnosis of R. tigrinus bites
R. tigrinus bites were diagnosed based on the detailed infor-
mation of snakes that patients observed and hemorrhagic
symptoms including severe hypofibrinogenemia, and
final diagnosis was recorded in a file of the Japan Snake
Institute.
We also applied DIC diagnostic criteria for critically ill
patients, as outlined by the Japanese Association of Acute
Medicine (JAAM criteria) [4]; DIC was defined as a total
score of ≥4.Treatment of R. tigrinus bites
The antivenom used against R. tigrinus bites was experi-
mentally manufactured [1]. Severe adverse effects exclu-
sively refer to anaphylactic shock in which the patient is
at a risk of death because of antivenom administration.
Data collection
The following parameters were recorded: age, gender,
date of injury, clinical symptoms, laboratory data, and
DIC score as well as treatment-related factors and the
outcomes including hospital mortality and renal failure
requiring hemodialysis.
Outcome measures
The primary endpoint of the present study was to deter-
mine the association between antivenom administration
and hospital mortality. The secondary outcome was to
determine the association between antivenom adminis-
tration and renal failure requiring hemodialysis after the
acute phase of injury.
Primary data analysis
Statistical analysis was performed using JMP version 11
(SAS, Cary, NC, USA). Patient characteristics, treatment-
related factors, and outcomes were compared between the
antivenom group and the without antivenom group using
Mann–Whitney U test and χ2 test or, where appropriate,
the Fisher exact test for categorical variables. P values
of ≤0.05 alpha were considered statistically significant.
Results
Demographic data and clinical characteristics of all study
patients
Over the 43-year study period, 34 patients were identified;
the patient characteristics are summarized in Table 1. We
further analyzed 25 cases from the previous study [3]. All
patients, except for one, were male, with a median age of
37.5 years. On admission, the median levels of fibrinogen
and fibrinogen degradation products (FDPs) were 35 mg/dL
and 200 μg/mL, respectively, and platelet counts were
107,000/mm3. The mean DIC score was 5.
Antivenom was administered to 19 patients, and the
median interval between bite and antivenom administra-
tion was 32 h. No apparent adverse effects were observed.
DIC was treated with heparin in 14 patients. Seven pa-
tients developed renal failure requiring hemodialysis after
the acute phase of the injury, and the in-hospital mortality
rate for all the patients was 11.8%.
Comparison of clinical characteristics between the
antivenom and without antivenom groups
The comparison of clinical characteristics between the
antivenom and without antivenom groups is summa-
rized in Table 2. Baseline characteristics and laboratory
Table 1 Population characteristics, n = 34
Population characteristics Values
Age (years) 37.5 (43.8)
Gender, male, n (%) 33 (97.1)




Nasal bleeding, n (%) 4 (11.8)
Gum bleeding, n (%) 15 (44.1)
Bleeding from the bite sites, n (%) 27 (79.4)
Headache, n (%) 6 (17.6)
Laboratory data
Platelet counts (×104/mm3) 10.7 (10.4)
Fibrinogen (mg/dL) 35 (30)
PT-INR 5 (4.38)
FDP (μg/mL) 200 (180)
DIC score 5(3)
Treatment
Heparin, n (%) 14 (41.2)
FFP, n (%) 8 (25.0)
PE, n (%) 4 (11.8)
Antivenom, n (%) 19 (55.9)
Time interval between getting Yamakagashi
bites and antivenom administration (h)
32 (31)
Severe adverse effects related to antivenom 0 (0)
Outcome
Mortality, n (%) 4 (11.8)
Hospital stay 9.5 (9.5)
Renal failure requiring hemodialysis, n (%) 7 (20.6)
Data are presented as median (interquartile, IQR) for continuous variables and
n (percentage) for categorical variables. PT-INR prothrombin time international
ratio, FDP fibrinogen degradation products, DIC disseminated intravascular
coagulation, FFP fresh frozen plasma, PE plasma exchange, SD standard
deviation.





group (n = 15)
P value
Age (years) 37 (40) 43 (50) 0.93
Gender, male, n (%) 18 (94.7) 15 (100) 1.00
Date of injury, year
(2000–2013), n (%)
7 (36.8) 2 (13.3) 0.24
Clinical symptoms
Nasal bleeding, n (%) 1 (5.3) 3 (20.0) 0.07
Gum bleeding, n (%) 8 (42.1) 7 (46.7) 1.00
Bleeding from the
bite sites, n (%)
16 (84.2) 11 (73.3) 0.67




12.5 (10.1) 7.9 (11.6) 0.21
Fibrinogen (mg/dL) 42.5 (20) 31 (43) 0.34
PT-INR 5.84 (4.24) 2.81 (4.11) 0.1
FDP (μg/mL) 236 (185) 160 (214) 0.06
DIC score 5 (4) 4.5 (3) 0.6
Treatment
Heparin, n (%) 4 (21.1) 10 (66.7) 0.01
FFP, n (%) 3 (15.8) 5 (38.5) 0.22
PE 1 (5.3) 3 (20.0) 0.30
Data are presented as median (interquartile, IQR) for continuous variables and
n (percentage) for categorical variables. PT-INR prothrombin time international
ratio, FDP fibrinogen degradation products, DIC disseminated intravascular
coagulation, FFP fresh frozen plasma, PE plasma exchange, SD standard deviation.
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groups.
Heparin use in the antivenom group was significantly
lower than that in the without antivenom group (21.1%
vs. 66.7%, P = 0.01).
Correlations between antivenom administration and
outcomes
Hospital mortality in the antivenom group was signifi-
cantly better than that in the without antivenom group
(0% vs. 26.7%, P = 0.03) (Figure 1). Moreover, the number
of patients developing renal failure requiring hemodialysis
was significantly lower in the antivenom group (5.3% vs.
40.0%, P = 0.03) (Figure 2).Discussion
In the present study, we demonstrated that hospital mortal-
ity and the number of renal failure requiring hemodialysis
following the acute phase of R. tigrinus bites were signifi-
cantly better in patients receiving antivenom than in those
not receiving antivenom. Previously, we demonstrated
that the pathophysiology of R. tigrinus bites involves DIC
with the fibrinolytic phenotype [3]. However, it seems that
this DIC with fibrinolysis phenomenon does not persist
throughout hospitalization and may be limited to the
acute injury phase. The present survey revealed that in the
acute phase, patients developed DIC with the fibrinolytic
phenotype; however, 40% of patients without antivenom
developed renal failure requiring hemodialysis in the later
phase of the injury. Renal pathology has revealed that
glomerular fibrin thrombi and tubular necrosis are re-
sponsible for renal failure associated with R. tigrinus bites
[5]. Indeed, Gando et al. reported that 24 to 48 h after se-
vere traumatic injury, DIC with the fibrinolytic phenotype
changes to DIC with the thrombotic phenotype, which
can result in the fatal multiple organ dysfunction
syndromes (MODS) [6,7].
Figure 1 Comparison of hospital mortality between the antivenom and the without-antivenom groups. Hospital mortality in the
antivenom group was significantly better than that in the without antivenom group (0% vs. 26.7%, P = 0.03).
Figure 2 Comparison of the number of patients developing renal failure requiring hemodialysis between the antivenom and the
without antivenom groups. The number of patients developing renal failure requiring hemodialysis was significantly lower in the antivenom
group (5.3% vs. 40.0%, P = 0.03).
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treatment of DIC is the specific and vigorous treatment
of the underlying disorder [6]. Considering our current
understanding of the pathophysiology of R. tigrinus bites,
it is obvious that managing DIC with heparin is contrain-
dicated in the acute phase because patients develop bleed-
ing manifestations [8]. On the other hand, antivenom
represents a specific, definitive, and effective treatment in
this phase. It appeared that administering R. tigrinus anti-
venom following bites can lead to complete clinical recov-
ery without progression to MODS, even in the presence of
severe DIC. Thus, antivenom effectively treats the acute
symptoms and can prevent disease progression. If there
is appropriate preparedness for anaphylaxis, antivenom
should be used in patients with R. tigrinus bites.
A major adverse effect of antivenom is serum sickness
disease, which usually occurred in 4–10 days after admin-
istration of antivenom [9]. Rashes, itching, joint pain, fever,
lymphadenopathy, malaise, and renal failure are typical
symptoms [9,10]. Because the number of patients develop-
ing renal failure requiring hemodialysis was significantly
lower in the antivenom group, the close association
between antivenom administration and renal failure was
not considered. In the present study, although the num-
bers in the present survey are still too low to make any
comprehensive assessment, the initial anaphylactic reac-
tion rate was also lower than the 2.4%–9% rate observed
with G. blomhoffii antivenom [11,12].
There are many limitations to the present study. Not-
ably, the present study had a retrospective design and a
relatively small sample size. Selection bias may also have
been an issue because only cases reported to our center
were used, and many cases may have remained undiag-
nosed or misdiagnosed because of the unfamiliar symp-
toms presented by this rare snakebite. Finally, because
tissue plasminogen activator (t-PA) was not evaluated,
the primary activation of fibrinogenolysis remains un-
clear. Furthermore, plasminogen activator inhibitor-1
(PAI-1), which induces the suppression of fibrinolysis,
was not evaluated. Further study is required to clarify
the pathophysiology of R. tigrinus bites.
Conclusions
In our small retrospective study, antivenom administra-
tion was likely to be effective in the management of R.
tigrinus bites. Apparently, further research is required to
confirm its efficacy.
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